Press Releases and Events

PRESS RELEASES

Press Release | January 6, 2026

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

READ MORE
Press Release | January 5, 2026

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

READ MORE
Press Release | January 5, 2026

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

READ MORE
Press Release | January 4, 2026

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

READ MORE
Press Release | December 18, 2025

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

READ MORE
Press Release | December 18, 2025

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

READ MORE
Press Release | December 11, 2025

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | December 3, 2025

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

READ MORE
Press Release | November 20, 2025

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

READ MORE
2 / 24